SecBot SecBot
Biotech Drug Report Generated Nov 12, 2026

XEN1120

XENE·Xenon Pharmaceuticals Inc.
NEUTRAL
Drug Impact Rating3/10
Trial phase
Phase 1 completed; advancing to Phase 2
Time to market
XEN1120 has completed Phase 1 and is advancing to Phase 2 proof-of-concept studies expected in H1 2027. Even if Phase 2 succeeds, the drug would still need Phase 3 trials and FDA review, putting potential approval several years away (likely 2029-2031 at the earliest).
Why 3/10
XEN1120 has no hard binary catalyst (PDUFA or pivotal readout) scheduled within the next ~12 months. The next milestone is the initiation of Phase 2 proof-of-concept studies in acute pain, expected in H1 2027, which is a non-binary operational update. XEN1120 is an early-stage asset at a company whose primary value driver is azetukalner, so even positive Phase 2 news would have limited impact on the stock.
Actionable Insight NEUTRAL

Watch for the initiation of Phase 2 proof-of-concept studies for XEN1120 in acute pain, expected in H1 2027. The more immediate catalysts for Xenon stock are the December 2026 X-NOVA2 MDD topline readout for azetukalner and the FDA's review of the azetukalner NDA for focal seizures. XEN1120 is too early-stage to drive material share-price moves on its own.

Price Chart

Loading chart...

Executive Summary

XEN1120 is an investigational Kv7 potassium channel opener being developed by Xenon Pharmaceuticals (XENE, Nasdaq) as a non-opioid treatment for acute pain. On October 29, 2026, Xenon announced positive Phase 1 results at the IASP 2026 conference, showing XEN1120 achieved plasma levels predictive of analgesic effects and was generally well-tolerated. The company plans to advance XEN1120 (alongside its NaV1.7 pain candidate XEN1701) to Phase 2 proof-of-concept studies in acute pain, expected to begin in the first half of 2027. XEN1120 is an early-stage pipeline asset; Xenon's primary value driver is azetukalner (XEN1101), a Kv7 opener with an NDA submitted for focal seizures and a Phase 3 depression readout expected in December 2026. Xenon held $1.15B in cash as of September 30, 2026, funding operations into 2029.

How It Works

XEN1120 is a Kv7 potassium channel opener. Kv7 channels act like 'brakes' on nerve cells: opening them stabilizes the electrical activity of neurons and reduces excessive firing that transmits pain signals. This makes XEN1120 a non-opioid approach to treating acute pain, avoiding the addiction and respiratory-depression risks of opioids.

Trial Status

Positive Phase 1 results announced October 29, 2026 at IASP 2026. Phase 1 achieved target plasma levels predictive of analgesic effects with good tolerability. The company is advancing XEN1120 to Phase 2 proof-of-concept studies in acute pain, expected to begin in H1 2027.

The Two-Sided Case

▲ Bull Case4
Positive Phase 1 data showed XEN1120 achieved plasma levels predictive of analgesic effects and was generally well-tolerated, supporting advancement to Phase 2.
XEN1120 is a non-opioid pain candidate targeting a large market opportunity amid growing regulatory and societal pressure to reduce opioid prescribing.
Xenon has a deep cash position of $1.15B (as of September 30, 2026) providing runway into 2029, ample to fund XEN1120's Phase 2 development without near-term dilution risk.
The company's validated Kv7 potassium channel platform (azetukalner already in NDA review for epilepsy) provides technical confidence in the mechanism.
▼ Bear Case4
XEN1120 is an early-stage, pre-revenue asset with no approved products; Phase 2 proof-of-concept studies in acute pain have not yet begun and could fail to show efficacy.
The acute pain market is highly competitive with many established generic and branded non-opioid analgesics, making differentiation difficult even if Phase 2 succeeds.
XEN1120 is a small part of Xenon's pipeline; the company's stock is driven primarily by azetukalner (epilepsy NDA and depression Phase 3 readout), so XEN1120-specific news is unlikely to move shares materially.
Xenon voluntarily paused new enrollment in Phase 3 MDD and BPD studies of azetukalner in September 2026, raising questions about Kv7 class safety that could theoretically affect XEN1120 as another Kv7 channel opener.

Upcoming Catalysts

  • Initiation of Phase 2 proof-of-concept studies for XEN1120 in acute pain, expected H1 2027

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Xenon Pharmaceuticals Inc. 8-K XENE ·Originating report

Sources · 7

Hover a chip for the title
1 rttnews.com2 rttnews.com3 manilatimes.net4 marketscreener.com5 theglobeandmail.com6 markets.businessinsider.com7 sec.gov